Promising Outlook for Axsome Therapeutics Driven by Auvelity’s Strong Market Performance and Growth Prospects
Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) yesterday and set a price target ...
bovnews15h
How Does Dyne Therapeutics Inc (DYN) Stack Up Against Its Industry Peers?
Dyne Therapeutics Inc (DYN) stock saw a modest uptick, ending the day at $13.72 which represents a slight increase of $0.03 or 0.22% from the prior close of $13.69. The stock opened at $13.72 and ...
Now's the time to invest beyond U.S. stocks and bonds: Morgan Stanley's top wealth manager
A return to U.S. stock and bond prices moving together is a key reason why investors should curb equity risk by buying other assets such as commodities, Morgan Stanley Wealth Management said this week ...